Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase

Archives of Biochemistry and Biophysics

Volumn 475, Issue 2, 2008, Pages 93-99

  Kranendonk, Michel ^a   Marohnic, Christopher C ^b   Panda, Satya P ^b   Duarte, Maria Paula ^c   Oliveira, José Santos ^c   Masters, Bettie Sue Siler ^b   Rueff, José ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Adverse drug reactions; Antley Bixler syndrome; CYP1A2; Cytochrome P450; Drug metabolizing enzymes; NADPH cytochrome P450 oxidoreductase; P450 1A2; Polymorphism; POR; Protein protein interaction

Indexed keywords

2 AMINO 3 METHYLIMIDAZO[4,5 F]QUINOLINE; 2 AMINOANTHRACENE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CYTOCHROME C; CYTOCHROME P450 1A2; CYTOCHROME P450 REDUCTASE; ETHOXYRESORUFIN DEETHYLASE; FLAVINE ADENINE NUCLEOTIDE; LIVER ENZYME; TETRAZOLIUM BLUE;

ALLELE; ANTLEY BIXLER SYNDROME; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; MOLECULAR MODEL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOBIOTIC METABOLISM;

CATALYSIS; CRANIOSYNOSTOSES; CYTOCHROME P-450 CYP1A2; FLAVIN-ADENINE DINUCLEOTIDE; FORMAZANS; HUMANS; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; SYNDROME; TETRAZOLIUM SALTS; XENOBIOTICS;

BACTERIA (MICROORGANISMS);

EID: 44949214648     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2008.04.014     Document Type: Article

References (39)

1. Antley R., and Bixler D. Birth Defects Orig. Artic. Ser. 11 (1975) 397-401
2. Chun K., Siegel-Bartelt J., Chitayat D., Phillips J., and Ray P. Am. J. Med. Genet. 77 (1998) 219-224
3. Flück C., Tajima T., Pandey A., Arlt W., Okuhara K., Verge C., Jabs E., Mendonca B., Fujieda K., and Miller W. Nat. Genet. 36 (2004) 228-230
4. Huang N., Pandey A., Agrawal V., Reardon W., Lapunzina P., Mowat D., Jabs E., Van Vliet G., Sack J., Flück C., and Miller W. Am. J. Hum. Genet. 76 (2005) 729-749
5. Guengerich F. In: Ortiz de Montellano P. (Ed). Cytochrome P450 Structure, Mechanism and Biochemistry (2005), Kluwer, Academic/Plenum Publishers, New York 377-530
6. Arlt W., Walker E., Draper N., Ivison H., Ride J., Hammer F., Chalder S., Borucka-Mankiewicz M., Hauffa B., Malunowicz E., Stewart P., and Shackleton C. Lancet 363 (2004) 2128-2135
7. Fukami M., Horikawa R., Nagai T., Tanaka T., Naiki Y., Sato N., Okuyama T., Nakai H., Soneda S., Tachibana K., Matsuo N., Sato S., Homma K., Nishimura G., Hasegawa T., and Ogata T. J. Clin. Endocrinol. Metab. 90 (2005) 414-426
8. Hart S., Wang S., Nakamoto K., Wesselman C., Li Y., and Zhong X. Pharmacogenet. Genomics 18 (2008) 11-24
9. Han J., Wang S., He X., Liu C., and Hong J. Toxicol. Sci. 91 (2006) 42-48
10. Wang S., Han J., He X., Wang X., and Hong J. Drug Metab. Dispos. 35 (2007) 176-179
11. Kostrzewa-Nowak D., Paine M., Korytowska A., Serwatka K., Piotrowska S., Wolf C., and Tarasiuk J. Cancer Lett. 245 (2007) 252-262
12. Marohnic C., Panda S., Martasek P., and Masters B. J. Biol. Chem. 281 (2006) 35975-35982
13. Masters B.S., and Marohnic C. Drug Metab. Rev. 38 (2006) 209-225
14. Duarte M., Palma B., Laires A., Oliveira J., Rueff J., and Kranendonk M. Mutagenesis 20 (2005) 199-208
15. Kranendonk M., Fisher C., Roda R., Carreira F., Theisen P., Laires A., Rueff J., Vermeulen N., and Estabrook R. Mutat. Res. 439 (1999) 287-300
16. Duarte M., Palma B., Gilep A., Laires A., Oliveira J., Usanov S., Rueff J., and Kranendonk M. Mutagenesis 22 (2007) 75-81
17. Dhir V., Ivison H., Krone N., Shackleton C., Doherty A., Stewart P., and Arlt W. Mol. Endocrinol. 21 (2007) 1958-1968
18. Pandey A., Kempna P., Hofer G., Mullis P., and Flück C. Mol. Endocrinol. 21 (2007) 2579-2595
19. Kranendonk M., Carreira F., Theisen P., Laires A., Fisher C., Rueff J., Estabrook R., and Vermeulen N. Mutat. Res. 441 (1999) 73-83
20. Kranendonk M., Mesquita P., Laires A., Vermeulen N., and Rueff J. Mutagenesis 13 (1998) 263-269
21. Fisher C., Caudle D., Martin-Wixtrom C., Quattrochi L., Tukey R., Waterman M., and Estabrook R. FASEB J. 6 (1992) 759-764
22. Yim S., Yun C., Ahn T., Jung H., and Pan J. J. Biochem. Mol. Biol. 38 (2005) 366-369
23. Burke M., Thompson S., Weaver R., Wolf C., and Mayer R. Biochem. Pharmacol. 48 (1994) 923-936
24. Chauret N., Gauthier A., and Nicoll-Griffith D. Drug Metab. Dispos. 26 (1998) 1-4
25. Duarte M., Palma B., Gilep A., Laires A., Oliveira J., Usanov S., Rueff J., and Kranendonk M. Mutagenesis 20 (2005) 93-100
26. Wang M., Roberts D., Paschke R., Shea T., Masters B., and Kim J. Proc. Natl. Acad. Sci. USA 94 (1997) 8411-8416
27. Hlavica P., Schulze J., and Lewis D. J. Inorg. Biochem. 96 (2003) 279-297
28. Pikuleva I., Cao C., and Waterman M. J. Biol. Chem. 274 (1999) 2045-2052
29. Zhang H., Im S., and Waskell L. J. Biol. Chem. 282 (2007) 29766-29776
30. Hughes A., Powell D., Bard M., Eckstein J., Barbuch R., Link A., and Espenshade P. Cell Metab. 5 (2007) 143-149
31. Kurzban G., and Strobel H. J. Chromatogr. 358 (1986) 296-301
32. Kurzban G., and Strobel H. J. Biol. Chem. 261 (1986) 7824-7830
33. Kurzban G., Howarth J., Palmer G., and Strobel H. J. Biol. Chem. 265 (1990) 12272-12279
34. Jenkins C., Genzor C., Fillat M., Waterman M., and Gomez-Moreno C. J. Biol. Chem. 272 (1997) 22509-22513
35. Jenkins C., and Waterman M. J. Biol. Chem. 269 (1994) 27401-27408
36. Jenkins C., and Waterman M. Biochemistry 37 (1998) 6106-6113
37. Shet M., Fisher C., and Estabrook R. Arch. Biochem. Biophys. 339 (1997) 218-225
38. Waterman M., Jenkins C., and Pikuleva I. Toxicol. Lett. 82-83 (1995) 807-813
39. Nebert D., and Russell D. Lancet 360 (2002) 1155-1162